Despite a steady stream of headlines suggesting they will transform the future of healthcare, high-tech regenerative medicines have, to date, been quite inaccessible to patients, with only eight having been granted an EU marketing licence in the last 7 years. Here, we outline some of the historical reasons for this paucity of licensed innovative regenerative medicines. We discuss the challenges to be overcome to expedite the development of this complex and rapidly changing area of medicine, together with possible reasons to be more optimistic for the future.
Several factors have contributed to the scarcity of cutting-edge regenerative medicines in clinical practice. These include the great expense and difficulties involved in planning how individual therapies will be developed, manufactured to commercial levels and ultimately successfully delivered to patients. Specific challenges also exist when evaluating the safety, efficacy and cost-effectiveness of these therapies. Furthermore, many treatments are used without a licence from the European Medicines Agency, under “Hospital Exemption” from the EC legislation. For products which are licensed, alternative financing approaches by healthcare providers may be needed, since many therapies will have significant up-front costs but uncertain benefits and harms in the long-term. However, increasing political interest and more flexible mechanisms for licensing and financing of therapies are now evident; these could be key to the future growth and development of regenerative medicine in clinical practice.
Recent developments in regulatory processes, coupled with increasing political interest, may offer some hope for improvements to the long and often difficult routes from laboratory to marketplace for leading-edge cell or tissue therapies. Collaboration between publicly-funded researchers and the pharmaceutical industry could be key to the future development of regenerative medicine in clinical practice; such collaborations might also offer a possible antidote to the innovation crisis in the pharmaceutical industry.
The complex science behind ‘cure for blindness’ headlines [ http://www.telegraph.co.uk/wellbeing/health-advice/science-health-eyes-blindness-advice-James-leFanu-doctor/]. Accessed 14 Feb 2017.
Chandran S. What are the prospects of stem cell therapy for neurology? BMJ (Clinical research ed). 2008;337:a1934. CrossRef
House of Lords Science and Technology Committee. Regenerative medicine report. London: The Stationery Office Limited; 2013.
Exploring the assessment and appraisal of regenerative medicines and cell therapy products [ https://www.nice.org.uk/Media/Default/About/what-we-do/Science%20policy%20and%20research/final-york-report-march-16.pdf]. Accessed 2 May 2016.
Hettle RCM, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017. Ahead of print.
U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Adaptive design clinical trials for drugs and biologics. Draft guidance; 2010. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Accessed 14 Feb 2017.
Unverzagta S, Prondzinsky R, Peinemannc F. Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review. J Clin Epidemiol. 2013;66:1271–80. CrossRef
Lucas F. Medicines Adaptive Pathways to Patients (MAPPs) – opportunities and challenges in Europe. Value & Outcomes Spotlight 2015. https://www.ispor.org/ValueOutcomesSpotlightResources/health-policy_MAPPS_Europe.PDF. Accessed 14 Feb 2017.
ADAPTSMART. Accelerated Development of Appropriate Patient Therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes. [ http://adaptsmart.eu/]. Accessed 11 Sept 2015.
Department of Health. Accelerated access review: final report. Review of innovative medicines and medical technologies; 2016. https://www.gov.uk/government/publications/accelerated-access-review-final-report. Accessed 14 Feb 2017.
Cell Therapy Catapult to create cutting-edge global manufacturing site in Stevenage . [ https://ct.catapult.org.uk/-/cell-therapy-catapult-to-create-cutting-edge-global-manufacturing-site-in-stevenage##]. Accessed 9 Sept 2015.
Garrison Jr LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16:703–19. CrossRefPubMed
Towse A. Regenerative medicine: a European HTA perspective. In: ISPOR 17th Annual European Congress . Amsterdam; 2014. https://www.ispor.org/Event/GetReleasedPresentation/107. Accessed 14 Feb 2017.
European Commission. Report from the Commission to the European Parliament and the Council in accordance with Article 25 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Brussels; 2014. http://ec.europa.eu/health//sites/health/files/files/advtherapies/2014_atmp/atmp_en.pdf.
Thomas R, Heathman A, Nienow W, McCall MJ, Coopman K, Bo Kara B, et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med. 2015;10:49–64. CrossRef
Levine BL, June CH. Perspective: Assembly line immunotherapy. Nature (London) 2013;498:S17.
Medicine Manufacturing Industry Partnership. Advanced therapies manufacturing action plan: retaining and attracting advanced therapies manufacture in the UK; 2016. Available from: http://www.abpi.org.uk/our-work/mmip/Documents/Advanced-Therapies-Manufacturing-Taskforce-report.pdf. Accessed 14 Feb 2017.
Europe approves Holoclar®, the first stem cell-based medicinal product. Thursday, 26/02/2015 [ http://www.eurostemcell.org/story/europe-approves-holoclar-first-stem-cell-based-medicinal-product]. Accessed 12 Feb 2016.
Strimvelis to be the start of a whole new gene therapy platform for GSK and partners [ http://www.fiercebiotech.com/financials/strimvelis-to-be-start-of-a-whole-new-gene-therapy-platform-for-gsk-and-partners]. Accessed 11 Aug 2016.
- Innovative regenerative medicines in the EU: a better future in evidence?
Mark S. Corbett
- BioMed Central
Neu im Fachgebiet Allgemeinmedizin
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II